共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
4.
5.
In this review, the authors' works published within the past 5 years devoted to the development of bifunctional hybrid nanostructures based on the targeting polypeptides and nanoparticles of various origin (quantum dots, nanogold, nanodiamonds, upconversion nanoparticles, magnetic and polymer nanoparticles) as modules that ensure visualization and various damaging effects on cancer cells are surveyed and the prospects of their application in theranostics and precision medicine have been contemplated. 相似文献
6.
MARY M. CAMERON 《American anthropologist》2006,108(3):558-559
Toward an Integrative Medicine: Merging Alternative Therapies with Biomedicine. Hans Baer. Lanham, MD: AltaMira Press, 2005. 203 pp. 相似文献
7.
胃癌是消化系统最常见的恶性肿瘤之一,全球每年胃癌新发病例数接近百万,严重影响着人类健康.近年来医学领域发展迅速,不管是胃癌的手术方式,还是放疗、化疗等治疗手段均获得了较大提高.但是由于缺乏有效早期诊断方法,大多数胃癌患者确诊时已进入疾病晚期,所以尽管医学技术不断发展,胃癌的死亡率依然居高不下.随着对胃癌分子机制的不断深入研究,一种直接作用于胃癌主要信号转导通路上某一特定靶点的新型治疗方式-分子靶向治疗逐渐成为当前肿瘤研究的热点.目前已有多种单克隆抗体及小分子靶向药物进入临床,用于人体多种肿瘤的治疗并呈现较好疗效.分子靶向治疗的出现为进展期肿瘤患者带来了新的希望.本文主要就进展期胃癌分子靶向治疗现状以及最新研究进展作一综述. 相似文献
8.
9.
Marcy Rosenbaum 《Medical anthropology quarterly》2000,14(4):630-632
Preventing and Controlling Cancer in North America:. Cross-Cultural Perspective. Diane Weiner. ed. Westport, CT: Praeger Publishers, 1999. xvii. 245 pp.
Evaluating Alternative Cancer Therapies:. Guide to the Science and Politics of an Emerging Medical Field. David J. Hess. New Brunswick, NJ: Rutgers University Press, 1999. xxi. 260 pp. 相似文献
Evaluating Alternative Cancer Therapies:. Guide to the Science and Politics of an Emerging Medical Field. David J. Hess. New Brunswick, NJ: Rutgers University Press, 1999. xxi. 260 pp. 相似文献
10.
Transgenic Research - 相似文献
11.
Summary . Cancer registry records contain valuable data on provision of adjuvant therapies for cancer patients. Previous studies, however, have shown that these therapies are underreported in registry systems. Hence direct use of the registry data may lead to invalid analysis results. We propose first to impute correct treatment status, borrowing information from an additional source such as medical records data collected in a validation sample, and then to analyze the multiply imputed data, as in Yucel and Zaslavsky (2005, Journal of the American Statistical Association 100, 1123–1132). We extend their models to multiple therapies using multivariate probit models with random effects. Our model takes into account the associations among different therapies in both administration and probability of reporting, as well as the multilevel structure (patients clustered within hospitals) of registry data. We use Gibbs sampling to estimate model parameters and impute treatment status. The proposed methodology is applied to the data from the Quality of Cancer Care project, in which stage II or III colorectal cancer patients were eligible to receive adjuvant chemotherapy and radiation therapy. 相似文献
12.
Rosarin Sruamsiri Dennis Ross-Degnan Christine Y. Lu Nathorn Chaiyakunapruk Anita K. Wagner 《PloS one》2015,10(3)
Background
Increasing access to clinically beneficial targeted cancer medicines is a challenge in every country due to their high cost. We describe the interplay of innovative policies and programs involving multiple stakeholders to facilitate access to these medicines in Thailand, as well as the utilization of selected targeted therapies over time.Methods
We selected two medicines on the 2013 Thai national list of essential medicines (NLEM) [letrozole and imatinib] and three unlisted medicines for the same indications [trastuzumab, nilotinib and dasatinib]. We created timelines of access policies and programs for these products based on scientific and grey literature. Using IMS Health sales data, we described the trajectories of sales volumes of the study medicines between January 2001 and December 2012. We compared estimated average numbers of patients treated before and after the implementation of policies and programs for each product.Results
Different stakeholders implemented multiple interventions to increase access to the study medicines for different patient populations. During 2007–2009, the Thai Government created a special NLEM category with different coverage requirements for payers and issued compulsory licenses; payers negotiated prices with manufacturers and engaged in pooled procurement; pharmaceutical companies expanded patient assistance programs and lowered prices in different ways. Compared to before the interventions, estimated numbers of patients treated with each medicine increased significantly afterwards: for letrozole from 645 (95% CI 366–923) to 3683 (95% CI 2,748–4,618); for imatinib from 103 (95% CI 72–174) to 350 (95% CI 307–398); and for trastuzumab from 68 (95% CI 45–118) to 412 (95% CI 344–563).Conclusions
Government, payers, and manufacturers implemented multi-pronged approaches to facilitate access to targeted cancer therapies for the Thai population, which differed by medicine. Routine monitoring is needed to assess clinical and economic impacts of these strategies in the health system. 相似文献13.
Manon Deville Roberto Natalini Clair Poignard 《Bulletin of mathematical biology》2018,80(12):3184-3226
We propose a mathematical model to describe enzyme-based tissue degradation in cancer therapies. The proposed model combines the poroelastic theory of mixtures with the transport of enzymes or drugs in the extracellular space. The effect of the matrix-degrading enzymes on the tissue composition and its mechanical response are accounted for. Numerical simulations in 1D, 2D and axisymmetric (3D) configurations show how an injection of matrix-degrading enzymes alters the porosity of a biological tissue. We eventually exhibit numerically the main consequences of a matrix-degrading enzyme pretreatment in the framework of chemotherapy: the removal of the diffusive hindrance to the penetration of therapeutic molecules in tumors and the reduction of interstitial fluid pressure which improves transcapillary transport. Both effects are consistent with previous biological observations. 相似文献
14.
Shelley R. Adler 《Medical anthropology quarterly》1999,13(2):214-222
The legacy of 19th-century social theories applied to the study of non-mainstream treatment use continues to affect contemporary research into complementary and alternative medicine (CAM). Quantitatively based studies of CAM use have been hindered by the lack of an adequate lexicon, inaccurate characterizations of the people who use CAM, and underestimates of the prevalence of usage. Results from a qualitative prospective cohort study challenge previous stereotypes by indicating that CAM usage does not increase dramatically with the initial diagnosis of cancer and that younger women are more likely to use CAM than older women. Qualitative research methods are uniquely appropriate for obtaining accurate information about health practices that, despite growing acceptance in some areas of society, are still viewed as outside of the mainstream. 相似文献
15.
K Veskimäe M Scaravilli W Niininen H Karvonen S Jaatinen M Nykter T Visakorpi J Mäenpää D Ungureanu S Staff 《Translational oncology》2018,11(5):1160-1170
Ovarian cancer has the highest mortality rate of all gynecologic malignancies. Identification of new biomarkers is highly needed due to its late diagnosis and high recurrence rate. The objective of this study was to identify mechanisms of therapy resistance and potential biomarkers by analyzing mRNA and protein expression from samples derived from patients with platinum-sensitive and -resistant ovarian cancer (total cohort n?=?53). The data revealed new candidates for targeted therapies, such as GREB1 and ROR2. We showed that the development of platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated. Moreover, we demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways. Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model. The results of the present study provided insight into molecular mechanisms associated with platinum resistance that could be further investigated to improve treatment strategies in this clinically challenging gynecological cancer. 相似文献
16.
Background
Breast cancer survivors have an increased risk of bone fracture. But the risk among young patients with adjuvant therapies remains unknown. This population-based study is aimed to assess the incidence and risk of fracture among young (age of 20 to 39 years) breast cancer patients who received adjuvant therapies.Methods
From January 2001 to December 2007, 5,146 newly diagnosed breast cancer patients were enrolled from the National Health Insurance Research Database (NHIRD) in Taiwan. Patients were observed for a maximum of 6 years to determine the incidence of newly onset fracture. Kaplan Meier and Cox regression analyses were used to evaluate the risk of fracture in young breast cancer patients who received adjuvant treatments.Results
Of the total 5,146 young (age of 20 to 39 years) breast cancer patients, the Cox multivariate proportional hazards analysis showed that AIs, radiotherapy, and monoclonal antibodies were significantly associated with a high risk of fracture. Moreover, patients who received AIs for more than 180 days had a high hazard ratio (HR) of 1.77 (95% CI = 0.68–4.57), and patients who received more than four radiotherapy visits had a high HR of 2.54 (95% CI = 1.07–6.06). Under the site-specific analysis, young breast cancer patients who received AIs had the highest risk of hip fracture (HR = 8.520, 95% CI = 1.711–42.432, p < 0.04), whereas patients who received radiotherapy had the highest risk of vertebral fracture (HR = 5.512, 95% CI = 1.847–16.451, p < 0.01).Conclusion
Young breast cancer patients who are receiving AIs, radiotherapy or monoclonal antibody need to be more careful for preventing fracture events. Breast cancer treatment plans are suggested to incorporate fracture prevention interventions. 相似文献17.
18.
19.
Anton Wulf Christensen Simon Tarp Daniel E. Furst Anna D?ssing Kirstine Amris Henning Bliddal Peter C. Taylor Robin Christensen 《PloS one》2015,10(9)